Sana Biotechnology, Inc. (SANA) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US7995661045
Sana Biotechnology, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -250.32 m USD |
| EBIT | -244.17 m USD |
| Net income | -244.17 m USD |
| Diluted EPS – continuing operations | -0.96 USD |
Full history since 2018, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Sana Biotechnology, Inc.
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company's product pipeline includes UP421, a HIP-modified allogeneic primary islet cell product, which is in phase 1 clinical trial to treat type 1 diabetes; SC451, a HIP-modified, stem cell derived pancreatic islet cell therapy, which is in preclinical trial for the treatment of type 1 diabetes; SG293 and SG299, a CD8-targeted fusosome for the treatment of B cell hematologic malignancies and B cell mediated autoimmune diseases. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company has a strategic collaboration with Mayo Clinic for the development of SC451, a hypoimmune-modified pancreatic islet cell therapy for type 1 diabetes. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.
More stocks
- Suzhou Shijia Science & Technology Inc (002796.SZ)
- Founders Metals Inc. (FDR.V)
- Wuxi Huadong Heavy Machinery Co Ltd (002685.SZ)
- Wuhan Xianglong Power Industry Co Ltd (600769.SS)
- Besalco Sa (BESALCO.SN)
- RED RIVER BANCSHARES INC (RRBI)
- North Atlantic Smaller Companies Investment Trust PLC (NAS.L)
- ContextLogic Holdings Inc. (LOGC)
- Shanghai Chengdi Constr Co (603887.SS)
- Risesun Real Estate Development Co Ltd (002146.SZ)
- LivsMed (491000.KQ)
- Chicony Power Technology Co Ltd (6412.TW)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.